Biotech Values

[DewDiligence]

I saw that you have Achillion on your favorites list, and on the [SI charity] contest list for 2010. Their Hep C data was early stage, and the Hep C space is crowded, but I assume you were impressed?

I was not unduly impressed by the early ACH-1625 data (#msg-44566075); however, I thought ACHN’s valuation, even after the recent run-up, was low enough to be worth a 5% weight in the charity contest.